In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 40 for your search:

Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Aromatase Inhibitor Clinical Trial

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 70
Sponsor: NIGMS
Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001YGB11, 2012-003689-41, NCT01743560

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 0120070323, NCT00698971

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: TENBC, NCT01648608

Phase III Randomized Study of Adjuvant Therapy Comprising Tamoxifen Citrate Followed By Either Anastrozole, Letrozole, or Exemestane Versus Anastrozole, Letrozole, or Exemestane Alone in Postmenopausal Women With Resected Endocrine-Responsive Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: GIM-3-FATA, GIM3-FATA, EUDRACT-2006-004018-42, EU-20764, NCT00541086

Phase III Randomized Study of Fulvestrant With or Without Lapatinib Tosylate and/or Aromatase Inhibitor Therapy in Postmenopausal Women With Metastatic Breast Cancer That Progressed After Prior Aromatase Inhibitor Therapy. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GIM-GIM8-OVER, GIM8-OVER, EUDRACT-2007-006031-30, EU-20853, GSK-GIM-GIM8-OVER, ZENECA-GIM-GIM8-OVER, OVER, NCT00688194

10.

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: CDR0000635986, COL-MNEMOSYNE, 2007-12, INCA-RECF0899, EUDRACT-2008-003620-32, MNEMOSYNE, NCT00893061

11.

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: SHBCC0701, NCT00902954

12.

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02623, S1007, CDR0000692475, U10CA032102, SWOG-S1007, NCT01272037

13.

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Arobase (GINECO-BR107), NCT01303679

14.

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DETECT III, 2010-024238-46, NCT01619111

15.

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001JDE49, NCT01626222

16.

A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: GBG 54, 2009-015122-11, NCT01638247

17.

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271

18.

Phase I/II Randomized Pilot Study of Neoadjuvant Therapy Comprising Sunitinib Malate and Exemestane in Postmenopausal Women With Hormone Receptor-Positive and HER-2 Negative Primary Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Postmenopausal
Sponsor: Other
Protocol IDs: ICO-SUT-EXE-08, SUT-EXE-08, PFIZER-ICO-SUT-EXE-08, NCT00931450

19.

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D2610C00003, 2010-021220-10, NCT01202591

20.

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 2010-535, NCT01484041

21.

A Trial of AZD4547 for Breast Cancer That is Oestrogen Receptor Positive and Has Got Worse Despite Having Anastrozole or Letrozole

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 25 and over
Sponsor: Other
Protocol IDs: C/23/2011, 2011-000454-32, NCT01791985

22.

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000595712, SINGAPORE-NCC0706, NCC0706, NCT00687648

23.

Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WCI1534-08, NCT00941330

24.

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018286, 212082BCA2001, 2011-000621-80, NCT01381874

25.

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 50 to 80
Sponsor: Other
Protocol IDs: CH-BC-011, NCT01431053

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map